In accordance with the previous research reporting that inhibition of GATA6/VCAM-1 contributed to the anti-atherosclerotic effect of RARα/RXRα agonists in Apoe-/- mice 38, the current study revealed that a similar mechanism is shared by both human and mouse arterial EC that also accounts for the beneficial effect of Romidepsin on the suppression of atherosclerosis. Here, VCAM1 is linked to atherosclerosis.